US Hospital Spending Report: Remdesivir Takes the Lead

A recently spending report released by Vizient shows that Remsdesivir, the COVID-19 treatmetn by Gilead Sciences Inc, was the medicine hospitals spent the most on. The report, which details spending data from October 2020 to September 2021, reveals that the drug accounted for 3.42% of all member spending.

According to Deena Beasley in Reuters, “Gilead, which will report quarterly results on Tuesday, posted $4.2 billion in global Veklury sales in the first nine months of 2021. Wall Street expects fourth-quarter sales of $864 million, as compiled by Refinitiv.”

Read more by clicking here.

(Source: Reuters, February 1^st, 2022)